Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 5,030,000 shares, a decline of 6.0% from the January 15th total of 5,350,000 shares. Based on an average daily volume of 882,500 shares, the days-to-cover ratio is presently 5.7 days. Approximately 9.1% of the shares of the stock are short sold.

Insiders Place Their Bets

In related news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.93% of the stock is owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Large investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. boosted its holdings in Agios Pharmaceuticals by 2.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock valued at $35,152,000 after purchasing an additional 25,600 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Agios Pharmaceuticals by 8.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,835 shares of the biopharmaceutical company’s stock valued at $4,036,000 after purchasing an additional 9,606 shares during the last quarter. Voloridge Investment Management LLC boosted its holdings in Agios Pharmaceuticals by 2.1% in the fourth quarter. Voloridge Investment Management LLC now owns 200,481 shares of the biopharmaceutical company’s stock valued at $6,588,000 after purchasing an additional 4,082 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at about $5,337,000. Finally, Twinbeech Capital LP purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at about $4,636,000.

Wall Street Analyst Weigh In

Several equities analysts recently commented on AGIO shares. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank upped their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Finally, Royal Bank of Canada upped their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $33.61 on Wednesday. Agios Pharmaceuticals has a 1 year low of $26.19 and a 1 year high of $62.58. The firm has a market cap of $1.92 billion, a P/E ratio of 2.96 and a beta of 0.88. The stock has a 50-day simple moving average of $34.64 and a 200-day simple moving average of $43.21.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 2,051.38% and a negative return on equity of 2.93%. On average, equities research analysts predict that Agios Pharmaceuticals will post -0.46 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.